For specific questions, other outcomes were included to inform decision-making, including TTR as a surrogate for bleeding and thrombosis, impairment of quality of life, critical INR as a surrogate for bleeding and thrombosis, increased duration of hospitalization, medication adherence as a surrogate for bleeding and thrombosis, and delay of intervention. Some studies reported outcomes differently from what the panel determined to be critical or important for decision-making. Typically, outcomes are reported as any VTE, any PE, any DVT, any proximal DVT, or any distal DVT, sometimes preceded by asymptomatic or symptomatic. Table 1. Prioritized questions for optimal management of anticoagulation therapy Prioritized questions 1. In obese patients receiving LMWH therapy for treatment of acute VTE, should initial LMWH dose selection according to actual body weight vs dose selection based on a fixed maximum daily dose (i.e., capped dose) be used? 2. For patients requiring administration of inhibitors or inducers of P-gp or strong inhibitors or inducers of CYP enzymes, should a DOAC or an alternative anticoagulant be used for treatment of VTE? 3. For patients receiving maintenance VKA therapy for treatment of VTE, should point-of-care INR testing by the patient at home (PST) vs any other INR testing approach be used? 4. For patients receiving maintenance VKA therapy for treatment of VTE, should point-of-care INR testing by the patient at home and self-adjustment of VKA dose (PSM) vs any other management approach be used? 5. For patients receiving VKA therapy for treatment of VTE, should a shorter INR recall interval vs a longer INR recall interval be used following VKA dose adjustment due to an out-of-target-range INR? 6. 